Multiple Sclerosis Flashcards

(36 cards)

1
Q

Immune-mediated disease of the CNS that is associated with inflammation, demyelination, axonal loss/neurodegeneration/atrophy in both white and grey matter

A

Multiple Sclerosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Most common cause of non-traumatic disability in young adults

A

MS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

There is a higher incidence of MS in

A

Women

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

EBV infection, vitamin D insufficiency, smoking tobacco, and obesity are all environmental risk factors for

A

MS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

In a brain with MS, we see

A

White matter plaques

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Induces conduction blocks in structurally intact axons, drives demyelination, and induces transection of axons (with consequent conduction block) within acute lesions

A

Lymphocyte-driven inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Activated microglial cells might contribute to the repair mechanisms that lead to

A

Remyelination or to the degeneration of axons

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Redistribution of sodium channels along demyelinated axons could restore

A

Conduction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Astrocytic activation and proliferation (gliosis) might impede

A

Repair

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Focal disturbances of function >24 hours

–Occur on average once a year in untreated patients

A

MS Relapse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

MS relapses occur in the absence of

A

Environmental, metabolic, or infectious processes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

At least one objective clinical episode with neurological symptoms lasting for 24 hours or longer (with no symptomatic infection)* is required for diagnosis of

A

Relapsing-Remitting MS (RRMS)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

We also need dissemination in time and space to diagnose with

A

RRMS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

One year of disease progression is needed to diagnose with

A

Primary-Progressive MS (PPMS)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

We use blood tests to exclude MS mimics such as

A

Lyme Disease or B12 Deficiency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is an infectious disease that mimics MS?

17
Q

What are four inflammatory diseases that mimic MS?

A

SLE, Sarcoidosis, Neuromyelitis, and ADEM

18
Q

Cervical or thoracic spondylosis also mimics

19
Q

Often a monophasic demyelinating disease

-May be induced by viruses or vaccination

20
Q

The most common tick-transmitted disease in the northern hemisphere

-Caused by spirochetes of the Borrelia burgdorferi species complex

21
Q

Frequently indistinguishable from MS on both clinical and radiologic grounds. Patients may have focal neurologic deficits, relapsing–remitting disease

22
Q

Brain WM abnormalities with MS-like features are found in approximately

A

75% of lyme patients

23
Q

Characterized by a specific IgG antibody marker (NMO antibody)

A

Neuromyelitis Optica Spectrum Disorders (NOSD)

24
Q

The target antigen in NMOSD is a water channel abundant in the CNS called

25
Characterized by inflammatory demyelination in the CNS, for example in the optic nerves and spinal cord
NMOSD
26
What is used to treat acute MS relapses?
High dose IV steroids or ACTH
27
What is a common high-dose IV steroid used to treat acute MS relapse?
Methylprednisone
28
2nd generation fumaric acid ester used as a disease modifying treatment for MS
BG 12
29
Monoclonal antibody blocking adhesion of VLA-4 positive T cells to VCAM-1 positive endothelial cells -used as SMT
Natalizumab
30
S1P receptor agonist used as DMT
Fingolimod
31
Monoclonal antibody targeting and deleting CD20 positive B cells -Used as DMT
Ocrelizumab
32
Increases risk of infections and malignancies
Ocrelizumab
33
Has been shown to cause PML in 0.3% of treated patients
Natalizumab
34
What are two DMTs for secondary progressive MS (SPMS) and Primary Progressive MS (PPMS)
Mitoxantrone and Ocrelizumab
35
Has been approved by FDA for SPMS but is not commonly used due to potential serious adverse effects
Mitoxantrone
36
Approved for PPMS in 2017
Ocrelizumab